Jump to main content

TAKHZYRO (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

Site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

Freedom from Daily Dosing

TAKHZYRO is an injection taken under the skin. No reconstitution is needed, and it comes ready to use in a prefilled syringe. Explore more information about TAKHZYRO dosing and administration.

1

MINUTE TO
SELF-INJECT
for most people in the
clinical studies*

2

WEEKS
BETWEEN
EACH DOSE

3

CHOICES FOR
INJECTION SITE
stomach, thigh or upper arm

*Most adolescents and adults in the clinical studies self administered TAKHZYRO within 10 to 60 seconds. These injection times are based on vial administration.

TAKHZYRO is a plasma-free, subcutaneous (under-the-skin) injection that you give yourself just once every 2 weeks with a ready-to-use, single-dose, prefilled syringe.

The recommended dose for people 12 years of age and older is 300 mg every 2 weeks. If you experience zero attacks for more than 6 months, your doctor may consider prescribing TAKHZYRO 300 mg every 4 weeks.

Before starting treatment with TAKHZYRO, you will receive training to ensure you know how to administer your therapy. Do not attempt to take TAKHZYRO without first being trained by a healthcare provider.

TAKHZYRO dosing at a glance

Dosing schedule
Once every 2 weeks (starting dose)
How long to administer
One minute or less for most people
How much volume
2 mL
Administration
Subcutaneous injection
How supplied
Ready-to-use, single-dose, prefilled syringe
How stored
Keep refrigerated between 36°F and 46°F (2°C and 8°C)

Please see full Prescribing Information for detailed dosage and administration information.

Give TAKHZYRO 2.5 months to reach steady state if you're an adult or adolescent

With your first dose of TAKHZYRO, the medicine will start to build up in your body. Over the course of your first 6 doses, TAKHZYRO will reach a constant level—also known as "steady state." Once you get there, it's important to keep taking TAKHZYRO exactly as prescribed to help maintain steady state. It takes about 6 doses of TAKHZYRO for the amount of medication to become constant in your body.

Take TAKHZYRO as prescribed by your doctor. Do not miss or skip doses.

STEADY STATE
(about 70 days)
dose 1 dose 2 dose 3 dose 4 dose 5 dose 6
month
2.5
dose 7

Need a refresher on your TAKHZYRO injection training?

Explore training materials

View Transcript

Get some tips from people experienced with taking TAKHZYRO.

JACK: Injecting TAKHZYRO has not been a problem for me. For one, I only have to inject it once every two weeks. Plus, it's subcutaneous, which means it's under the skin, not in the vein. That feels manageable for me.

KELLY: Being able to switch up injection sites is a big plus for me personally, that and the fact that I can go two weeks between injections.

SORAYA: After I was trained how to do it, injecting has been manageable for me. I can do it myself, and it takes about a minute. It's an important thing I can do for myself to help reduce the frequency and severity of my HAE attacks.

DENNIS: I was having a hard time prepping the medication the way the OnePath nurse showed me. Luckily, my wife was able to do it, and I just watched her a few times. And now I am proud to say I can do it myself.

ANDREW: The actual injection takes about a minute, and then I'm free from thinking about my next dose for two weeks.

NARRATOR: TAKHZYRO (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema, HAE, in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age. TAKHZYRO may cause serious side effects including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms, wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash hives.

NARRATOR: The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant and breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding or plan to breastfeed.

NARRATOR: Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.

A healthcare provider will show you the right way to use TAKHZYRO.

Explore Training Materials

More support for taking TAKHZYRO

Now that you’re on TAKHZYRO, it’s important to keep taking it as prescribed. Our tips and tools can help you stay on track, so you can stay focused on your treatment goals.

FIND TIPS TO STAY ON TRACK